Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

Dow Jones

06/17

0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company "looks like it could continue to deliver mid-teen EPS growth." (mike.cherney@wsj.com)

(END) Dow Jones Newswires

June 16, 2025 22:15 ET (02:15 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544360933"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544360933\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544360933?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544360933","market":"other","top_or_hot":-1,"title":"Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" (mike.cherney@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2025 22:15 ET (02:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHigher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-17 10:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" (mike.cherney@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2025 22:15 ET (02:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2544360933","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544360933","pubTimestamp":1750126500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED"},"translate_title":"CSL的Andembry提供更高的利润率将提高盈利——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9,"CSL":1},"content_text":"0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" (mike.cherney@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2025 22:15 ET (02:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}